FEMY FEMASYS INC

Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023

Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023

ATLANTA, March 09, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, announced today that Kathy Lee-Sepsick, founder, president & chief executive officer, will participate in the South By Southwest (SXSW) 2023 Conference being held in Austin, Texas from March 10-19, 2023.

Kathy Lee-Sepsick will participate in a panel discussion titled “The Post-Roe Fertility Journey” on March 11, 2023 at 10:00 am CT, which will discuss what considerations are needed in women’s health for protection during fertility management and family building in the post-Roe era.

About Femasys

Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s products currently marketed in the United States, include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling. To learn more, visit or follow us on and .

Contacts:

Investors

Chuck Padala

LifeSci Advisors, LLC



Femasys Inc.

Investor Contact:



Media Contact:





EN
09/03/2023

Underlying

FEMYFEMASYS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FEMASYS INC

 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP ...

Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access -- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that its FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program (MDSAP)....

February 26, 2026 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Receives AMA CPT Editorial Panel Approval for New Category III...

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination -- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that it has received notice from the American Medical Association (AMA) CPT Editorial Panel approving a new, unique Category III Current Procedural ...

February 23, 2026 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Expands European Commercial Footprint with Swiss Partner for F...

Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products -- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe -- ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution partnership with to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent Birth Contr...

February 3, 2026 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with ...

Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced that on January 13, 2026, it received notification from The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq approved the Company's request for an additional 180-calendar day extension to regain compliance with the minimum closing bid price require...

January 14, 2026 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Announces Partnership with Refuah Health Center to Expand Firs...

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population ATLANTA , Jan. 13, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Refuah Health Center to offer FemaSeed as a first step in the infertility treatment process. Th...

January 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch